Imatinib
About
Therapy type: Targeted therapy
Therapy strategy: Bcr-Abl inhibition, c-Kit inhibition, PDGF-R inhibition
Mappings
NCI Thesaurus: Imatinib (ncit:C62035)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (2) HC (2) | BCR::ABL1 | Chronic Myelogenous Leukemia | Imatinib | |
| FDA (2) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Imatinib | |
| FDA (2) HC (2) | BCR::ABL1 | Acute Lymphoid Leukemia | Imatinib | |
| FDA (1) HC (1) | PDGFRA rearrangements | Myelodysplastic Syndromes | Imatinib | |
| FDA (1) HC (1) | PDGFRB rearrangements | Myelodysplastic Syndromes | Imatinib | |
| FDA (1) HC (1) | KIT p.D816V | Aggressive Systemic Mastocytosis | Imatinib | |
| FDA (1) HC (1) | FIP1L1::PDGFRA | Chronic Eosinophilic Leukemia, NOS | Imatinib | |
| FDA (1) HC (2) | CD117 + | Gastrointestinal Stromal Tumor | Imatinib | |
| FDA (1) | FIP1L1::PDGFRA | Gastrointestinal Stromal Tumor | Imatinib | |
| HC (1) | PDGFRA rearrangements | Myeloproliferative Neoplasm | Imatinib | |
| HC (1) | PDGFRB rearrangements | Myeloproliferative Neoplasm | Imatinib |